Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Mar 15;3(3):100570.
doi: 10.1016/j.xcrm.2022.100570.

Precision medicine in pediatric severe asthma: Targeted blockade of type 2 inflammation

Allyson S Larkin  1 , Sally E Wenzel  2
Affiliations
Comment

Precision medicine in pediatric severe asthma: Targeted blockade of type 2 inflammation

Allyson S Larkin et al. Cell Rep Med. .

Abstract

A study by Bacharier et al. demonstrated that children with uncontrolled moderate-to-severe asthma with elevated type 2 biomarkers who received dupilumab had fewer exacerbations and better lung function.1 These results highlight precision medicine approaches in pediatric asthma.

PubMed Disclaimer

Conflict of interest statement

S.E.W. is co-principal investigator on an investigator-initiated study of dupilumab with Regeneron. There are no other conflicts of interest.

Figures

Figure 1
Figure 1
Biomarkers and biologic therapies for type 2 high asthma Although both adults and children can have a type 2 high phenotype, allergic disease is more commonly associated with severe pediatric asthma. A blood sample measuring total and specific IgE as well eosinophils and measurement of FeNO can help predict response to various type 2 high targeted therapies. Created with BioRender.com.
See this image and copyright information in PMC

Comment on

  • Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.
    Bacharier LB, Maspero JF, Katelaris CH, Fiocchi AG, Gagnon R, de Mir I, Jain N, Sher LD, Mao X, Liu D, Zhang Y, Khan AH, Kapoor U, Khokhar FA, Rowe PJ, Deniz Y, Ruddy M, Laws E, Patel N, Weinreich DM, Yancopoulos GD, Amin N, Mannent LP, Lederer DJ, Hardin M; Liberty Asthma VOYAGE Investigators. Bacharier LB, et al. N Engl J Med. 2021 Dec 9;385(24):2230-2240. doi: 10.1056/NEJMoa2106567. N Engl J Med. 2021. PMID: 34879449 Clinical Trial.

References

    1. Bacharier L.B., Maspero J.F., Katelaris C.H., Fiocchi A.G., Gagnon R., de Mir I., Jain N., Sher L.D., Mao X., Liu D., et al. Liberty Asthma VOYAGE Investigators Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. N. Engl. J. Med. 2021;385:2230–2240. doi: 10.1056/NEJMoa2106567. - DOI - PubMed
    1. Wenzel S.E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 2012;18:716–725. doi: 10.1038/nm.2678. - DOI - PubMed
    1. Fitzpatrick A.M., Moore W.C. Severe Asthma Phenotypes - How Should They Guide Evaluation and Treatment? J. Allergy Clin. Immunol. Pract. 2017;5:901–908. doi: 10.1016/j.jaip.2017.05.015. - DOI - PMC - PubMed
    1. Reddel H.K., Bacharier L.B., Bateman E.D., Brightling C.E., Brusselle G.G., Buhl R., Cruz A.A., Duijts L., Drazen J.M., FitzGerald J.M., et al. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. J. Allergy Clin. Immunol. Pract. 2022;10:S1–S18. doi: 10.1016/j.jaip.2021.10.001. - DOI - PubMed
    1. Brusselle G.G., Koppelman G.H. Biologic Therapies for Severe Asthma. N. Engl. J. Med. 2022;386:157–171. doi: 10.1056/NEJMra2032506. - DOI - PubMed